An open-label, randomized, parallel group, multicentre study to compare estradiol suppression between Zoladex 10.8 mg depot given 3 monthly and Zoladex 3.6 mg depot given monthly in pre-menopausal patients with ER positive early breast cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Goserelin (Primary)
- Indications Early breast cancer
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 24 Mar 2010 Results presented at 7th European Breast Cancer Conference (EBCC-7), 2010.
- 29 Dec 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History